Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

Movement Disorders

Volumn 23, Issue 10, 2008, Pages 1353-1360

  Brin, Mitchell F ^a,b   Comella, Cynthia L ^c   Jankovic, Joseph ^d   Lai, Francis ^a   Naumann, Markus ^e   Ahmed, Fayyaz ^f   Brashear, Allison ^f   Chehrenama, Mahan ^f   Erjanti, Hanna ^f   Evatt, Marian ^f   Gordon, Mark Forrest ^f   Grimes, David ^f   Hauser, Robert ^f   Hefter, Harald ^f   Hermanowicz, Neil ^f   Ilmavirta, Matti ^f   Jennings, Danna ^f   Jolma, Tapani ^f   Kaiňovský, Petr ^f   Knecht, Stefan ^f   Martinez Castrillo, Juan Carlos ^f   Massey, Janice M ^f   Molho, Eric ^f   Miyasaki, Janis ^f   Rajput, Alex ^f   Reiners, Karlheinz ^f   Ružčka, Evžen ^f   Schramm, Axel ^f   Seeberger, Lauren ^f   Sherman, Scott ^f   Subramanian, Thyagarajan ^f   Suchowersky, Oksana ^f   Swope, David ^f   Tsui, Joseph ^f   Velickovic, Miodrag ^f   Walker, Francis ^f   more..

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e KLINIKUM AUGSBURG   (Germany)

^f Klinikum Augsburg ^*

Author keywords

Antigenicity; Botulinum toxin; Cervical dystonia; Immunogenicity; Neutralizing antibodies

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY LABELING; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CERVICAL DYSTONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSTONIA; FACE MUSCLE; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INJECTION SITE PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NECK PAIN; OPEN STUDY; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BIOLOGICAL ASSAY; BOTULINUM TOXIN TYPE A; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MIDDLE AGED; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; TORTICOLLIS;

EID: 52649113805     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22157     Document Type: Article

References (30)

1. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-957.
2. Tarsy D, Simon DK. Dystonia. N Engl J Med 2006;355:818-829.
3. Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998;121(Part 4):547-560.
4. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000;55(12 Suppl 5):S29-S35.
5. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40:1213-1218.
6. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004;19(Suppl 8): S109-S115.
7. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 2001;71:193-199.
8. Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther 2005;22:49-55.
9. Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000;22:1516-1524.
10. Gordon MF, Barron R. Effectiveness of repeated treatment with botulinum toxin type A across different conditions. South Med J 2006;99:853-861.
11. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-1293.
12. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005;20:592-597.
13. Jankovic J, Hunter C, Dolimbek BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006;67:2233-2235.
14. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 2006;13(Suppl 1)A1-15.
15. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
16. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-1188.
17. BOTOX Prescribing Information. Allergan, Inc. Irvine, CA. October 2006.
18. Aoki KR. Immunologic and other properties of therapeutic botulinum toxin serotypes. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p 103-113.
19. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p 93-108.
20. Sesardic D, Jones RG, Leung T, Alsop T, Tierney R. Detection of antibodies against botulinum toxins. Mov Disord 2004;19 (Suppl 8):S85-S91.
21. Jankovic J. Clinical implications of antigenicity and immunoresistance. In: Brin M, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p 409-416.
22. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
23. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord 2004;19(Suppl 8):S68-S84.
24. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46:26-29.
25. Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007;29:683-690.
26. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20:981-990.
27. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002;249:57-63.
28. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246:265-274.
29. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-1429.
30. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-154.